share_log

Panbela Therapeutics | 10-Q: Q3 2024 Earnings Report

Panbela Therapeutics | 10-Q: Q3 2024 Earnings Report

Panbela Therapeutics | 10-Q：2024財年三季報
美股SEC公告 ·  2024/11/15 05:25

Moomoo AI 已提取核心訊息

Panbela Therapeutics reported zero revenue and a net loss of $7.2 million for Q3 2024, compared to a $7.8 million loss in Q3 2023. Research and development expenses decreased 10.2% to $6.1 million, while general and administrative costs remained flat at $1.1 million. The company ended the quarter with $142,000 in cash and a working capital deficit of $15.0 million.The company's ASPIRE trial for ivospemin in pancreatic cancer continues to progress, with 89 sites open across 10 countries. However, in August 2024, the primary CRO began terminating their relationship due to payment delays, leading the company to assume direct trial responsibility. Full enrollment is now anticipated by Q2 2025, with an interim analysis expected in early 2025.Post quarter-end, Panbela secured significant financing through a Note Purchase Agreement with Nant Capital, receiving $2.85 million from a Tranche A Note and expecting $9.15 million from a Tranche B Note by November 15, 2024. The notes are convertible into common stock at $0.37 per share and will mature in six months, bearing interest at 8% plus the Monthly SOFR Rate.
Panbela Therapeutics reported zero revenue and a net loss of $7.2 million for Q3 2024, compared to a $7.8 million loss in Q3 2023. Research and development expenses decreased 10.2% to $6.1 million, while general and administrative costs remained flat at $1.1 million. The company ended the quarter with $142,000 in cash and a working capital deficit of $15.0 million.The company's ASPIRE trial for ivospemin in pancreatic cancer continues to progress, with 89 sites open across 10 countries. However, in August 2024, the primary CRO began terminating their relationship due to payment delays, leading the company to assume direct trial responsibility. Full enrollment is now anticipated by Q2 2025, with an interim analysis expected in early 2025.Post quarter-end, Panbela secured significant financing through a Note Purchase Agreement with Nant Capital, receiving $2.85 million from a Tranche A Note and expecting $9.15 million from a Tranche B Note by November 15, 2024. The notes are convertible into common stock at $0.37 per share and will mature in six months, bearing interest at 8% plus the Monthly SOFR Rate.
Panbela Therapeutics報告在2024年第三季度的營業收入爲零，淨虧損爲720萬美元，相較於2023年第三季度的780萬美元虧損。研發費用下降了10.2%，降至610萬美元，而一般和行政費用保持在110萬美元不變。公司在季度末的現金爲142,000美元，運營資本赤字爲1500萬美元。公司針對胰腺癌的ivospemin ASPIRE試驗正在繼續推進，10個國家的89個站點已開放。然而，在2024年8月，主要的合同研究組織因付款延遲開始終止與公司的關係，導致公司承擔直接的試驗責任。現預計將在2025年第二季度完成全部招募，並預計在2025年初進行中期分析。在季度結束後，Panbel...展開全部
Panbela Therapeutics報告在2024年第三季度的營業收入爲零，淨虧損爲720萬美元，相較於2023年第三季度的780萬美元虧損。研發費用下降了10.2%，降至610萬美元，而一般和行政費用保持在110萬美元不變。公司在季度末的現金爲142,000美元，運營資本赤字爲1500萬美元。公司針對胰腺癌的ivospemin ASPIRE試驗正在繼續推進，10個國家的89個站點已開放。然而，在2024年8月，主要的合同研究組織因付款延遲開始終止與公司的關係，導致公司承擔直接的試驗責任。現預計將在2025年第二季度完成全部招募，並預計在2025年初進行中期分析。在季度結束後，Panbela通過與Nant Capital簽署的票據購買協議獲得了重要融資，從A輪票據中獲得了285萬美元，並預計在2024年11月15日之前從B輪票據中獲得915萬美元。這些票據可以以每股0.37美元的價格轉換爲普通股，並將在六個月內到期，利率爲8%加上月度SOFR利率。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

獨立文件8  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    英偉達
    NVDA
    -- 126.630
    特斯拉
    TSLA
    -- 302.800
    超微電腦
    SMCI
    -- 45.540
    Palantir
    PLTR
    -- 87.840
    Hims & Hers Health
    HIMS
    -- 39.860
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    特斯拉績後巨震，後市你怎麽看？
    特斯拉2024年Q4營收257.1億美元，同比增長2%，不及預期。Cybercab計劃2026年投產，預計車輛業務將於2025年恢復增長。面對特朗普回歸，特斯拉股價能否在2025年繼續攀升？
    TSLA收益預覽：猜測開盤價贏取獎勵！